| Literature DB >> 10444002 |
K Ono1, T Ohtomo, K Yoshida, Y Yoshimura, S Kawai, Y Koishihara, S Ozaki, M Kosaka, M Tsuchiya.
Abstract
A mouse monoclonal antibody, anti-HM1.24 (IgG2a/kappa), binds to a surface antigen preferentially overexpressed on multiple myeloma (MM) cells, and exhibits potent antitumor cell activity against MM cells by antibody-dependent cell-mediated cytotoxicity (ADCC). To develop an antibody-based immunotherapy against MM, a humanized anti-HM1.24 antibody, in which all FRs correspond to naturally processed human FRs, has been successfully constructed with the aid of both the hybrid variable region and two-step design methods. This humanized anti-HM1.24 antibody (IgG1/kappa) is able to effectively induce ADCC against human myeloma KPMM2 and ARH77 cells in the presence of human PBMCs as effectively as a chimeric anti-HM1.24 antibody. The humanized anti-HM1.24 antibody, therefore, could be expected as a potent immunotherapeutic agent for MM patients.Entities:
Mesh：
Substances：
Year: 1999 PMID： 10444002 DOI： 10.1016/s0161-5890(99)00029-2
Source DB: PubMed Journal: Mol Immunol ISSN： 0161-5890 Impact factor: 4.407